$CLDX News
Last published 2d ago
- 2d agoCLDXGUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - CELLDEX THERAPEUTICS INCEarnings Call TranscriptsYATIN SUNEJAH, Good morning, everyone. Welcome to Google and IAM Third Annual Healthcare Innovation Conference. My name is Yatin Suneja, one of the biotech analysts here at the firm. It is my pleasure to welcome our next
- 6d agoCLDXCelldex Therapeutics, Inc. - PRESS RELEASEEarnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 6d agoCLDXCelldex Reports Third Quarter Financial Results and Provides Corporate UpdateGlobeNewswireBest-in-disease results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 studies showed rapid, profound, sustained efficacy supporting barzolvolimab’s potential to be a transformational therapy in CSUBLA submission for
- 1w agoCLDXCelldex to Present at Upcoming Investor ConferencesGlobeNewswireHAMPTON, N.J., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in fireside chats at two upcoming investor conferences: The Guggenheim 3rd Annual Healthcare
- 1mo agoCLDXTopline Phase 3 EMBARQ CSU1 and CSU2 Results Call - CELLDEX THERAPEUTICS INCEarnings Call TranscriptsGood day, and thank you for standing by. Welcome to the Celldex Therapeutics webcast. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer sessio
- 2mo agoCLDXCelldex to Present at Upcoming Investor ConferenceGlobeNewswireHAMPTON, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the upcoming Cantor Global Healthcare Conference on September 10, 2026
- 3mo agoCLDXCelldex Reports Second Quarter Financial Results and Provides Corporate UpdateGlobeNewswireBarzolvolimab Phase 3 chronic spontaneous urticaria studies (EMBARQ-CSU 1 and 2) ongoing, topline data expected in Sept/Oct 2026; BLA submission planned for 2027Phase 3 barzolvolimab cold urticaria and symptomatic
- 3mo agoCLDXPhase 2 Topline PN Results Conference Call and Webcast - CELLDEX THERAPEUTICS INCEarnings Call TranscriptsThank you for standing by, and welcome to CELDEX's Phase 2 PN Data Call. Currently, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a ques
- 3mo agoCLDXCelldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo NodularisGlobeNewswireStudy did not meet key efficacy objectives Favorable safety profile consistent with prior studies, including with new 450mg loading dose and up to 300mgQ4W regimenProfound systemic mast cell depletion, as evidenced by
- 3mo agoCLDXCelldex Announces Planned Transition of Chief Financial OfficerGlobeNewswireHAMPTON, N.J., July 15, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that Sam Martin, Senior Vice President and Chief Financial Officer, has informed the Company of his plans to retire in 2027. Mr.
- 5mo agoCLDXCelldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual MeetingGlobeNewswireTreatment with barzolvolimab resulted in rapid, significant, and durable improvements in angioedema in patients with moderate to severe CSUSeven months after the completion of dosing (Week 76), up to 64% of patients
- 5mo agoCLDXCelldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual MeetingGlobeNewswireCDX-622 is a novel, bispecific antibody combining mast cell depletion and TSLP inhibition, two independent pathways contributing to multiple I&I diseasesCDX-622 targets the soluble form of stem cell factor (SCF),
- 5mo agoCLDXCelldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual CongressGlobeNewswire-- Flash talks on barzolvolimab clinical program in CSU and Cold Urticaria ---- Late-breaking poster presentation on CDX-622 -- HAMPTON, N.J., June 10, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today
- 6mo agoCLDXCelldex Reports First Quarter Financial Results and Provides Corporate UpdateGlobeNewswireEnrollment completed six months ahead of guidance in both barzolvolimab Phase 3 chronic spontaneous urticaria studies (EMBARQ-CSU 1 and 2); Topline data expected in Q4 26; BLA submission planned for 2027Phase 3
- 7mo agoCLDXCelldex to Present at Upcoming Investor ConferenceGlobeNewswireHAMPTON, N.J., April 13, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in a fireside chat at H.C. Wainwright's 4th Annual Inflammatory Skin Disease Virtual Conference
- 7mo agoCLDXCelldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewswireHAMPTON, N.J., April 06, 2026 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. ("Celldex" or the "Company") (NASDAQ:CLDX) today announced the closing of its previously announced underwritten public offering of 11,896,750
- 7mo agoCLDXCelldex Announces Pricing of $300 Million Public Offering of Common StockGlobeNewswireHAMPTON, N.J., April 01, 2026 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. ("Celldex" or the "Company") (NASDAQ:CLDX) today announced the pricing of an underwritten public offering of 10,345,000 shares of its common
- 7mo agoCLDXCelldex Announces Proposed Public Offering of Common StockGlobeNewswireHAMPTON, N.J., April 01, 2026 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. ("Celldex" or the "Company") (NASDAQ:CLDX) today announced that it has commenced an underwritten public offering for the sale of shares of
- 7mo agoCLDXCelldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026GlobeNewswire- Improvements seen across all six DLQI Domains indicating broad, beneficial impact on quality of life -- Data further demonstrates first-in-class and best-in-disease barzolvolimab profile - HAMPTON, N.J., March 27,
- 8mo agoCLDXCelldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026GlobeNewswire- Late breaking Poster Presentation at AAAAI -- Ability to retreat facilitates a real-world paradigm in which treatment for ColdU and SD may be intermittent with barzolvolimab - HAMPTON, N.J., March 01, 2026 (GLOBE
- 8mo agoCLDXCelldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026GlobeNewswire- Sustained off-treatment efficacy despite barzolvolimab clearance and normalization of tryptase, suggesting disease modification in patients with CSU treated for full 52 weeks -- Greatly improved quality of life and
- 8mo agoCLDXCelldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate UpdateGlobeNewswireEnrollment completed in both Phase 3 chronic spontaneous urticaria global registration studies (EMBARQ-CSU 1 and 2) six months ahead of guidance; Topline data expected in Q4 26; BLA submission planned for 2027Phase 3
- 8mo agoCLDXCelldex Completes Enrollment in Global Phase 3 Studies (EMBARQ-CSU1 and EMBARQ-CSU2) of Barzolvolimab in Chronic Spontaneous UrticariaGlobeNewswireEnrollment completed six months ahead of guidance, driven by significant unmet need for better treatments in CSUTopline data expected Q4 2026BLA submission planned for 2027 HAMPTON, N.J., Feb. 25, 2026 (GLOBE
- 8mo agoCLDXCelldex Announces Multiple Upcoming Presentations at AAAAI 2026 Supporting Barzolvolimab's First-in-Class and Best-in-Disease ProfileGlobeNewswireHAMPTON, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that multiple presentations from the Company's Phase 2 clinical trials of barzolvolimab in chronic spontaneous urticaria (CSU) and
- 9mo agoCLDXCelldex to Present at Upcoming Investor ConferencesGlobeNewswireHAMPTON, N.J., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in fireside chats at the following upcoming investor conferences: Guggenheim Emerging Outlook:
- 11mo agoCLDXCelldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic DermographismGlobeNewswireNo advanced therapies approved to treat ColdU and SD—diseases of misery that dramatically impact all aspects of patient lifeBarzolvolimab is the only drug in development to demonstrate clinical benefit in patients in
- 1y agoCLDXCelldex Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswireStrong execution and continued progress across pipeline Positive Phase 2 barzolvolimab data in Chronic Spontaneous Urticaria (CSU) demonstrating rapid, profound improvement in UCT7 scores with sustained disease control
- 1y agoCLDXCelldex Announces Appointment of Teri Lawver as Chief Commercial OfficerGlobeNewswireHAMPTON, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today announced the appointment of Teri Lawver as Senior Vice President, Chief Commercial Officer. Ms. Lawver is an accomplished global healthcare
- 1y agoCLDXCelldex to Present at Upcoming Investor ConferencesGlobeNewswireHAMPTON, N.J., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in fireside chats at the following upcoming investor conferences: Guggenheim 2nd Annual
- 1y agoCLDXCelldex Presents Additional Positive Data Demonstrating Barzolvolimab's Ability to Drive Rapid, Profound and Durable Complete Urticaria Control in Phase 2 Chronic Spontaneous Urticaria (CSU) StudyGlobeNewswireHAMPTON, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today new data on exploratory endpoints (UCT7) further demonstrating barzolvolimab's ability to improve urticaria control from the
- 1y agoCLDXCelldex Presents Results from Barzolvolimab Phase 2 Study in Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Demonstrating Sustained Efficacy and Favorable Safety Profile over 20 Week Placebo Controlled Treatment Period; Up to 66% of Patients with ColdU and 49% with SD Obtain Complete Response at Week 20GlobeNewswireFirst large, randomized, placebo-controlled study to demonstrate clinical benefit in patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD)All primary and secondary endpoints met with high statistical
- 1y agoCLDXCelldex Announces Initial Positive Results from Phase 1 Trial of CDX-622 Demonstrating Favorable Safety and PK Profile and Sustained Mast Cell InhibitionGlobeNewswire--Data from Phase 1 Study in healthy volunteers presented at CIA Biennial Symposium-- HAMPTON, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today positive data from the ongoing Phase 1 study
- 1y agoCLDXCelldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025GlobeNewswireHAMPTON, N.J., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today new data demonstrating rapid and strong efficacy regardless of baseline immunoglobulin E (IgE) levels in patients with chronic
- 1y agoCLDXCelldex Therapeutics, Inc. (CLDX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptEarnings Call Transcripts
- 1y agoCLDXCelldex to Present at Morgan Stanley 23rd Annual Global Healthcare ConferenceGlobeNewswireHAMPTON, N.J., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced that management will participate in a fireside chat today, September 9th, 2025, at the Morgan Stanley 23rd Annual
- 1y agoCLDXCelldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE)GlobeNewswireStudy met primary endpoint demonstrating barzolvolimab's ability to potently deplete mast cells in the gastrointestinal tractProfound mast cell depletion did not result in improved clinical outcomes providing direct
- 1y agoCLDXCelldex Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswireStrong execution and continued progress across pipeline Unprecedented data delivered from Phase 2 CSU study demonstrating profound, sustained complete response and improved quality of life 7 months after completion of
- 1y agoCLDXCelldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025GlobeNewswire77% of patients (150 mg Q4W) treated with barzolvolimab who had angioedema at baseline were angioedema free at Week 52Data further support barzolvolimab clinical benefit to patients with CSU HAMPTON, N.J., June 14,
- 1y agoCLDXCelldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025GlobeNewswireSeven months after the completion of dosing: 41% of patients (150 mg Q4W) continue to experience complete response (UAS7=0)48% of patients (150 mg Q4W) report that CSU no longer impacts their quality of life
- 1y agoCLDXCelldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data in Chronic Spontaneous Urticaria at EAACI 2025 CongressGlobeNewswireHAMPTON, N.J., June 10, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that data from the Company's Phase 2 study of barzolvolimab in chronic spontaneous urticaria will be presented at the EAACI
- 1y agoCLDXCelldex Therapeutics Announces Election of Denice Torres to its Board of DirectorsGlobeNewswireHAMPTON, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that Denice M. Torres has been elected to the company's Board of Directors. "We are excited to welcome
- 1y agoCLDXCelldex Reports First Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswireStrong execution and progress across pipeline with multiple key data read outs expected in 2025Late breaking oral presentation on Phase 2 CSU program at EAACI 2025 in JunePhase 3 barzolvolimab CSU studies enrollment
- 1y agoCLDXCelldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult to Treat DiseaseGlobeNewswireHAMPTON, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Celldex announced today the presentation of histology data from the Company's ongoing Phase 2 study of barzolvolimab in eosinophilic esophagitis (EoE). Biopsies taken
- 1y agoCLDXCelldex Therapeutics to Present at Upcoming Investor ConferencesGlobeNewswireHAMPTON, N.J., March 04, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in fireside chats at two upcoming conferences: TD Cowen 45th Annual Health
- 1y agoCLDXCelldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025GlobeNewswire- CDX-622 inhibits SCF and TSLP-dependent inflammatory signatures in human skin -- Phase 1 study in healthy volunteers ongoing - HAMPTON, N.J., March 03, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc.
- 1y agoCLDXCelldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025GlobeNewswire- Greatly improved patient quality of life and reduced disease impact in patients with CSU and CIndU -- 82% of CSU patients reported that symptoms no longer had an impact on their quality of life at Week 52 -- 60% of
- 1y agoCLDXCelldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate UpdateGlobeNewswireEnrollment ongoing in Phase 3 barzolvolimab CSU studies; Phase 3 program in CIndU under developmentPhase 2 barzolvolimab EOE study fully accrued; Phase 2 study initiated in atopic dermatitis; enrollment ongoing in Phase
- 1y agoCLDXCelldex Initiates Phase 2 Study of Barzolvolimab in Atopic DermatitisGlobeNewswireHAMPTON, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the Company has initiated a Phase 2 study of barzolvolimab in atopic dermatitis (AD) and that the study is
- 1y agoCLDXCelldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory DiseasesGlobeNewswireHAMPTON, N.J., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in the Company's Phase 1a study of CDX-622 in healthy volunteers. CDX-622
- 2y agoCLDXCelldex Therapeutics to Present at Upcoming Investor ConferencesGlobeNewswireHAMPTON, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in fireside chats at two upcoming conferences: Guggenheim Healthcare